Energy prices surge, "demand destruction" risk returns to market focus

汇通财经2026/03/20 10:30

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

⑴ As energy prices surge and geopolitical risks dominate the market, a term typically seen during oil crises and periods of soaring inflation—“demand destruction”—has returned to the forefront of traders’ discussions. Its core meaning refers to permanent consumption loss triggered by high prices or supply disruptions; not cyclical tightening, but a fundamental change in buyer behavior. ⑵ This week, escalating tensions in the Middle East and attacks on key energy infrastructure have driven oil and natural gas prices sharply higher, forcing the market to confront this risk once again. The wild swings in Brent crude, combined with tight refining margins and fragile logistics, have hedgers, policymakers, and macro funds all asking the same question: how close are we to the price threshold that will structurally suppress consumption? ⑶ Early signs are already emerging: energy-intensive industries are beginning to cut production, transportation demand is wavering at the margins, and emerging market importers are bearing the brunt due to currency pressures. As inflation expectations rise, central banks must weigh the dual dilemma of high prices and weakening demand. “Demand destruction” is the market’s warning that prices have exceeded the system’s capacity to absorb them. If the trends of the past week foreshadow the future, this risk may soon evolve from an early warning signal into the dominant theme of the next stage of macro narrative.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 9 - RBC expects the performance of most European building material products to gradually improve quarter-on-quarter in Q3, but notes that geopolitical uncertainties in the US will continue to drive up cost inflation and increase market volatility. RBC anticipates that sales in Europe will remain sluggish due to heatwaves and rising mortgage rates, while a weak US housing market and the lack of a significant hurricane season will prompt roofing material companies to enter a destocking cycle. The firm is more optimistic about Germany’s Heidelberg Group (HEIG.DE), upgrading its rating to “outperform,” and points out that the company has handled the challenging quarter caused by extreme weather far better than its peers. Due to severe cost headwinds such as rising diesel and natural gas prices, RBC downgraded the ratings of US and French construction companies Knife River (KNF.N) and Saint-Gobain (SGOB.PA) from “outperform” to “market perform.” (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them solely for the ease of the reader. Reuters assumes no liability for any damages or losses that may arise from the use of automated translation functions.)

路透社•2026/10/09 07:16

3D printing materials supplier Amaero (AMRO.US) restarts US IPO, fundraising drops 60% to $20 million

Amaero (AMRO.US) on Thursday resumed its initial public offering (IPO) plans in the United States and filed new documents with the U.S. Securities and Exchange Commission (SEC), revealing a reduced number of shares to be issued.

智通财经•2026/10/09 07:11

Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium, as the issue price drops to the lower limit of $14.

Early-stage biotechnology company TRex Bio has priced its IPO at the lower end of the range at $14 per share, raising $116.7 million and achieving a market capitalization of $384 million. The company will be listed on Nasdaq on Friday, with Eli Lilly expressing interest in increasing its stake.

智通财经•2026/10/09 07:09

Small molecule biotechnology company Iambic Therapeutics (IAM.US) IPO priced at $15-17 per share, aiming to raise $150 millions.

Iambic Therapeutics plans to raise $150 millions by issuing 9.4 million shares, with an offering price range of $15 to $17 per share.

智通财经•2026/10/09 07:08